Replication Study: Melanoma genome sequencing reveals frequent PREX2 mutations

  1. Stephen K Horrigan
  2. Pascal Courville
  3. Darryl Sampey
  4. Faren Zhou
  5. Steve Cai
  6. Reproducibility Project: Cancer Biology  Is a corresponding author
  1. Noble Life Sciences, United States
  2. BioFactura, United States
  3. TACGen, United States

Decision letter

  1. Roger J Davis
    Reviewing Editor; University of Massachusetts Medical School, United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article "Replication Study: Melanoma genome sequencing reveals frequent PREX2 mutations" for consideration by eLife. Your article has been reviewed by a Reviewing Editor and the evaluation has been overseen by Charles Sawyers as the Senior Editor.

The Reviewing Editor has drafted this decision to help you prepare a revised submission.

This manuscript describes a replication study that was designed to examine the reproducibility of a study that identified a role for PREX2 in prostate cancer. The replication study appears to have been performed correctly. However, there are a number of issues that are raised by the nature of the data that was obtained:

1) Introduction, paragraph two. This text refers to the identification of Prex2 mutations by Berger et al. This presentation ignores results reported by the same authors and others that have disputed this finding – this information was presented in the Registered report and should be repeated here.

2) The rapid tumor development detected in the xenograft assays using the control melanocyte tumor cells (compared with the target study) makes the detection of accelerated tumor growth in the PREX2-expressing cells extremely difficult. This should be explicitly stated in the Abstract. This is important because the failure to replicate is compromised by this finding and should be clearly noted in the Abstract.

3) The tumor size limit is reported to be 1.5cm3. This is consistent with the target study. However, many IACUC approvals allow tumor growth to only 1cm3 prior to euthanasia. The specific IACUC approval this instance should be confirmed.

https://doi.org/10.7554/eLife.21634.011

Author response

This manuscript describes a replication study that was designed to examine the reproducibility of a study that identified a role for PREX2 in prostate cancer. The replication study appears to have been performed correctly. However, there are a number of issues that are raised by the nature of the data that was obtained:

1) Introduction, paragraph two. This text refers to the identification of Prex2 mutations by Berger et al. This presentation ignores results reported by the same authors and others that have disputed this finding – this information was presented in the Registered report and should be repeated here.

Thank you for raising this point. We have revised the Introduction to include other papers that have not identified PREX2 as a significantly mutated gene in melanoma, including the results from the Cancer Genome Atlas Network on the genomic classification of cutaneous melanoma.

2) The rapid tumor development detected in the xenograft assays using the control melanocyte tumor cells (compared with the target study) makes the detection of accelerated tumor growth in the PREX2-expressing cells extremely difficult. This should be explicitly stated in the Abstract. This is important because the failure to replicate is compromised by this finding and should be clearly noted in the Abstract.

We agree and have revised the Abstract to more clearly describe this aspect of the replication in relation to the original study.

3) The tumor size limit is reported to be 1.5cm3. This is consistent with the target study. However, many IACUC approvals allow tumor growth to only 1cm3 prior to euthanasia. The specific IACUC approval this instance should be confirmed.

We have confirmed that for this project the IACUC (Noble Life Sciences Inc. IACUC#5-05-002SCI (Noble Study No: S06-106)) approved tumor growth to 1.5cm3 prior to euthanasia.

https://doi.org/10.7554/eLife.21634.012

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Stephen K Horrigan
  2. Pascal Courville
  3. Darryl Sampey
  4. Faren Zhou
  5. Steve Cai
  6. Reproducibility Project: Cancer Biology
(2017)
Replication Study: Melanoma genome sequencing reveals frequent PREX2 mutations
eLife 6:e21634.
https://doi.org/10.7554/eLife.21634

Share this article

https://doi.org/10.7554/eLife.21634